S_ary Two doses of megestrol acetate (MA) have been prospectively compared in a random fashion as treatment for cancer-related anorexia-cachexia syndrome (ACS) in 122 patients with progressive soft tissue sarcoma, colorectal lung, head and neck and renal cancer resistant to systemic chemotherapy. After 30 days of MA, 55% of patients receiving MA at 160 mg day-' reported an increase in appetite, 27% of patients no variation and 18% complained of a decrease in appetite. Patients treated with MA at 320 mg day-' reported an increase in appetite in 68% of cases, a stabilisation in 20% of cases and a decrease in 12%. Although an increase in appetite was more frequently observed in patients receiving MA at 320 mg day-', however this difference was not statistically significant (P = 0.305). After 30 days of MA, 31% of patients treated with MA at 160 mg day -showed an increase in body weight, 25% a stabilisation and 44% a decrease. In the group of patients treated with MA at 320 mg day-l, 45% reported an increase in body weight, 16% no change and 23% weight loss. Although there was a trend favouring the higher dose of MA, overall analysis however failed to detect any statistically significant difference between the two treatment arms (P=0.242). Twenty-seven patients pretreated with 160 mg day-'and 23 patients treated with 320 mg day-' received firtiher therapy with MA at the dose of 320 and 480 mg day-' respectively. In the group of 22 patients treated with 320 mg day-', four (18%) reported an increase in body weight, eight (36%) an improvement in appetite, but none had an increase in performance status. Among the 20 evaluable patients treated with 480 mg day-', two (10%) had an increase in body weight, four (20%) an improvement in appetite, but none reported an increase in performance status. No difference in median survival was detected between the two arms. Toxicity was mild and predictable. In conclusion, the data achieved in the present study confirm the clinical safety and effectiveness of oral MA in the management of ACS in patients with advanced cancer resistant to systemic chemotherapy. Moreover, data concening the dose escalation of MA dosage in unresponsive patients suggest that a step by step increase in MA dosage could be the best way of administering MA for the management of ACS and that the increase of MA dosage over 480 mg day-' will probably be useless in the vast majority of cases. Data on body weight suggest that after 2 weeks' therapy MA could be stopped or its dosage tailored to patients' needs since the majority of patients respond after only 15 days of MA.
The anorexia-cachexia syndrome (ACS) is represented by a severe wasting clinical condition characterised by anorexia and progressive depletion of caloric reserve, body fat and muscular tissues (De Wys, 1979) . ACS is characteristic of nearly 70% of patients with terminal neoplastic disease even if it may be present also in earlier stages of tumour growth (Brennan, 1981; De Wys, 1979; Tisdale, 1993) . The combination of anorexia and wasting is of great concern for both patient and his/her family and therefore it is important both physically and psychologically (De Wys, 1985) . Moreover, patients with weight loss have a shorter survival than those patients with stable weight. In fact, the median survival of patients affected by breast, colorectal and prostatic cancer without weight loss is approximately double that of patients who lost weight (De Wys, 1985) .
ACS usually develops progressively through a selfmaintaining cycle of anorexia, reduction in caloric intake, muscle wasting and infections (Brennan and Burt, 1981; Knox et al., 1983; Nixon et al., 1980; Young, 1977) . However, the biochemical mechanism underlying ACS is still not well understood and most probably it is multifactorial. Recent experimental investigations have demonstrated that circulating factors, such as TNF-z and -fi, IL-1, IL-6 and y-IFN, may produce anorexia in animal models through both a proteolytic/lipolytic mechanism and a direct action on the hypothalamus (Beck and Tisdale, 1987; Lowry and Moldawer. 1990; Ternell et al., 1987; Tisdale, 1993) . The most effective way of managing ACS would be an effective reduction in tumour load, but this may be an elusive goal in most cases since generally a significant proportion of patients with ACS have already been heavily pretreated and thus show a multidrug-resistant progressive neoplasm. Moreover, systemic chemotherapy itself may contribute in some cases to the worsening of anorexia probably via mechanisms different from those underlying ACS (Boneterre et al., 1988; De Wys, 1979; Parnes and Aisner, 1992) . Parenteral and/or enteral hyperalimentation may improve caloric intake significantly in patients with ACS, but to date there is no clear evidence that this costly and often uncomfortable procedure eventually results in an improvement in the patients' quality of life (Parnes and Aisner, 1992) .
The observation that appetite stimulation with significant gain in body weight is often associated with hormonotherapy with megestrol acetate in patients treated for prostatic adenocarcinoma, metastatic breast cancer or malignant melanoma has prompted several authors to explore the role of MA in cancer anorexia and cachexia (Creagan et al., 1989; Sedlacek, 1988; Tchekmedyian et al., 1986 Tchekmedyian et al., , 1992a Splinter, 1992) . A phase III trial of MA as first-line treatment for metastatic breast cancer showed that weight gain increased with MA dosage although objective tumour response rate was not dose-related (Abrams et al., 1992) . Thus, it is evident that MA anabolic effect is entirely independent of the antineoplastic activity of progestins, since these effects could also be detected in patients affected by hormone-insensitive malignant neoplasms. MA may have a true anabolic effect in addition to stimulation of appetite: in fact the differentiating activity of MA on a preadipocyte fibroblast cell (Hamburger et al., 1988) . Moreover, Loprinzi et al. (1993) these data it should be stressed that patient populations 1579 included in the aboxe reported trials differ significantly in terms of response analy sis and elegibility criteria such as the inclusion of patients on cytoreductixve therapies. Our data are also in accord with those reported by other authors xx-hich failed to find a strong statistically significant correlation betx-een MA dosage and its clinical effects on ACS. w-ithout significant differences betw-een 480 and 960 mg day' (Schmoll. 1992) . The reports by both Loprinzi et al. (1993) and Schmoll (1992) . on the basis of a cost-benefit analI sis. concluded that the most reasonable therapy for ACS w-ould be to start With the lou-est possible dose of MA. This is also confirmed by the observation of bodv >-eight gain in a significant proportion of women 'ith breast cancer taking only MA 160 mg day-1 (Willemse et al.. 1990 : Abrams et al.. 1992 .
Interestingly. in our study a small. but significant.
proportion of patients >x-ho did not respond to either doses of MA responded when MA dosage xx as increased b-160 mg day '. In fact. among 27 patients x-ho did not respond to previous therapy w-ith MA 160 mg day' and xx ere subsequently treated with 320 mg day '. five patients showed an increase in body w-eight and eight patients had an improxvement in appetite. In accordance A-ith the data reported by other authors (Feliu et al.. 1992 : Tchekmedyian et al.. 1992a Loprinzi et al.. 1993) . the results achiexed in the present study suggest that the majority of patients w-ill respond to the MA lower dose of 160 mg day '. How-exer. since a relatively small proportion of patients may respond when a 2-or 3-fold increase in MA dosage over 160 mg da-l is gix-en. treatment of ACS w-ith MA may be tailored to individual patients. In other w-ords, it seems rational to start with the lowxer dose of 160 mg day-1 and subsequently increase the dosage in case of non-response or stabilisation. or depending on the extension of disease. the presence of massiv-e visceral metastases and patients' general conditions. as also suggested by other authors (Heckmay r and Gatzmeier. 1992: Tchekmedyian et al.. 1992b; Loprinzi et al.. 1993) . The above reported considerations lead us to conclude that an increase of MA dosage over 480 mg day% may be useless especially if weighted against cost in terms of both patients' compliance and quality of life and budgetarimpact.
Another notewxorthly point is the length of MA treatment. Data on the effects of MA on body A-eight reported in our study show-that after only-15 days of therapy an improvement in body->-eight is achiexed in 2700 and 400o of patients treated respectively at 160 and 320 mg day'. After 30 days of MA these rates increase to 31°o and 450o with onlx a 4-5`0 improvement over data achiexved after only 15 dayvs of treatment. These data suggest that in tailoring the MA therapy to patients' needs MA could be stopped or its dosage could be adjusted after only 15 days of treatment since the majority of responding patients can be detected after only 2 x-eeks of MA. These data are in accord wvith the pharmacokinetic characteristics of MA. %x-hich showx a rapid peak in plasma concentrations after only 7 day s of therapy (Miller et al.. 1988) .
Ox-erall. the tw-o different doses of MA employ ed in our study have been quite wxell tolerated by most patients. Most of the adxverse exvents x ere mild and predictable. and no significant difference in the incidence and sexverity of sideeffects was seen between the twxo groups of treatment.
In conclusion. the data presented in the present study confirms the clinical safety and effectiveness of oral megestrol acetate in the management of anorexia cachexia sx-ndrome in patients with adxvanced cancer resistant to sy-stemic chemotherapy. Moreoxver. data concerning the dose escalation of MA dosage in unresponsixve patients suggest that a step-by-step increase in MA dosage wxould be the best wxav of administering MA for the manazement of ACS and that increases of MA dosage oxer 480 mg day--' xvill probably be useless in the xvast majority of cases. 
